NEW YORK (GenomeWeb News) – Former Monogram Biosciences CEO and Chairman William Young will become chairman of Biogen Idec at the beginning of 2010, when he will take over the job from Bruce Ross. Ross plans to complete his current term as director and then retire. Before he worked at Monogram, Young was COO and VP of Genentech and he worked at Eli Lilly.
In addition, Biogen Idec said that former Thermo Fisher Scientific President and CEO Marijn Dekkers will step down as a director of the firm, effective at the end of the year. Dekkers will take over as CEO of Bayer Healthcare on Jan. 1.
Former National Institutes of Health Director Elias Zerhouni has joined the board of directors at Danaher. Zerhouni served as head of NIH between 2002 and 2008. During his tenure, he undertook the Roadmap for Medical Research, which aims to increase collaboration between NIH's 27 institutes and centers and to pursue innovative and important research areas. Zerhouni currently is a senior advisor at Johns Hopkins University School of Medicine and a senior fellow for the Bill and Melinda Gates Foundation's Global Health Program.
Affymetrix this week named Andrew Last to the position of chief commercial officer. Prior to joining Affymetrix, Last served on the leadership team of BD Biosciences' cell analysis unit, where he was vice president of global marketing and strategic planning and general manager of BD's San Diego-based Pharmingen business.
Karen Nelson has been named director of the J. Craig Venter Institute campus in Rockville, Md. She joins Robert Friedman, who became director of JCVI's San Diego facility last year. Both report to Craig Venter, the institute's founder and president.
Nelson replaces Bob Strausberg, who is leaving JCVI on Jan. 8, 2010, to join the Ludwig Institute for Cancer Research as director for collaborative sciences. He will maintain a joint appointment at JCVI and will continue cancer genomic collaborations between JCVI and LICR.
James Wells, director of the University of California, San Francisco's small molecule discovery center, has been named winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his protein engineering research.
Wells, who spent nearly two decades at Genentech and founded Sunesis Pharmaceuticals, has integrated proteomics, cell biology, molecular biology and other approaches in his research to understand how signaling drives responses such as cell growth and death.
Doris Hafenbradl has joined BioFocus as senior director of biology and natural products. She previously was executive VP of Proteros Biostructures and she was an executive at GPC Biotech and worked at the Genomics Institute of the Novartis Research Foundation.
Oxford BioTherapeutics has tapped Michael Moore to serve as a non-executive chairman. Moore spent five years at the UK biotech firm Piramed, and he was research director of Xenova Group. He has held senior academic posts at the Paterson Institute for Cancer Research, Christie Hospital, and the Brunel Institute of Cancer Genetics and Pharmacogenomics, where he currently is still a professor.
Ceiba Solutions has named Tim Bonnert, Scott DePriest, and Rich Estrin, all formerly of Rosetta Biosoftware to work on its IT consulting team, the company said this week. The company also has brought in Susan Ward, a former executive at Wyeth and Sterling Winthrop, as an advisor to help design its Life Science Dashboard.
Sirius Genomics has appointed Chris Wagner to replace Brad Popovich as CEO. Popovich, who has been president and CEO for four years, will remain on the firm's board and will provide strategic support. Wagner was VP of business development at the company, and he also was VP of marketing and business development at Aspreva.
Osmetech Molecular Diagnostics has named John Bellano to be senior VP of commercial operations. Bellano recently was VP of sales at Third Wave Technologies, a position he held throughout and after Third Wave was acquired by Hologic, in 2008.
The Burnham Institute for Medical Research has appointed executive VP Gary Raisl to serve as CFO. Raisl was VP for finance and administration at the Institute for Systems Biology and he held the same position at the University of the Sciences, Neumann College and St. Gabriel's systems in Philadelphia.
On-Q-ity has named Gary Palmer the company's Chief Medical Officer. Palmer previously was VP of medical affairs at Genomic Health, and he has held leadership roles at Amgen and Kosan Biosciences. He also has been director of the Medical Breast Service at the University of California Davis Cancer Center, CMO at Mercy Health System, and a member of the adjunct faculty at UCD.
The Personalized Medicine Coalition said this week that it has appointed Navigenics Founder Dietrich Stephan along with Clay Marsh to serve on its board of directors. Stephan is founder and CEO of the recently created Ignite Institute, and he also founded Amnestix and Aeuon. He also previously served as a senior investigator in neurogenomics and deputy director of discovery research at the Translational Genomics Research Institute. Marsh is director of the Center for Critical Care and executive director of the Center for Personalized Medicine at The Ohio State University Medical Center.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People in the News, a weekly roundup of industry comings and goings.